KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Earnings and Valuation
This table compares KORU Medical Systems and 10x Genomics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $41.13 million | 4.79 | -$2.64 million | ($0.06) | -70.83 |
| 10x Genomics | $642.82 million | 3.94 | -$43.54 million | ($0.35) | -56.60 |
Insider and Institutional Ownership
58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 20.6% of KORU Medical Systems shares are held by insiders. Comparatively, 10.0% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
KORU Medical Systems has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for KORU Medical Systems and 10x Genomics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 1 | 1 | 4 | 0 | 2.50 |
| 10x Genomics | 3 | 9 | 4 | 0 | 2.06 |
KORU Medical Systems currently has a consensus target price of $6.50, indicating a potential upside of 52.94%. 10x Genomics has a consensus target price of $18.46, indicating a potential downside of 6.79%. Given KORU Medical Systems’ stronger consensus rating and higher probable upside, equities research analysts clearly believe KORU Medical Systems is more favorable than 10x Genomics.
Profitability
This table compares KORU Medical Systems and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -6.41% | -15.90% | -9.77% |
| 10x Genomics | -6.77% | -6.89% | -5.34% |
Summary
KORU Medical Systems beats 10x Genomics on 7 of the 13 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
